ReviewNature reviews. Neurology2016
Advances in markers of prodromal Parkinson disease.
Review in Nature reviews. Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 230 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Unravelling Dysfunctional Brain Networks in Patients With Parkinson's Disease Suffering From Presence Hallucination
Unravelling Dysfunctional Brain Networks in Patients With Parkinson's Disease Suffering From Hallucinations
Who cites it
230 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effect of Metabolic Syndrome on Parkinson's Disease: A Systematic Review.Clinics (Sao Paulo, Brazil) · 2021Pooled it
- SNPs in SNCA, MCCC1, DLG2, GBF1 and MBNL2 are associated with Parkinson's disease in southern Chinese population.Journal of cellular and molecular medicine · 2020Pooled it
- FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson's disease: A whole-brain multimodal imaging meta-analysis.NeuroImage. Clinical · 2019Pooled it
- Efficacy and Safety of Electroacupuncture on Insomnia in Parkinson's Disease: A Multicentre, Randomized, Controlled Trial.Movement disorders clinical practice · 2025Trial
- Trial
- Plasma urate concentrations and possible REM sleep behavior disorder.Annals of clinical and translational neurology · 2019Trial
- Peripheral Immune Alterations and T Cell Clonal Dynamics Across the Parkinson's Disease Spectrum.medRxiv : the preprint server for health sciences · 2026Article
- Changes in sleep characteristics in Parkinson's disease: a prospective 5-year follow-up study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026Article
- Proteo-metabolomic integration identifies stage-specific candidate biomarkers for Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Evaluating the Relationship Between Early Non-Motor Symptoms and Late Diagnosis of Parkinson's Disease Based on the PPMI Database From 2012 to 2018: A Retrospective Cross-Sectional Study.Health science reports · 2026Article
- Healthy Dietary Patterns and Risk of Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α-synuclein preformed fibrils-induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines.Brain pathology (Zurich, Switzerland) · 2026Article
- The Oral-Brain Axis: A Unified Framework Linking Trigeminal Sensorimotor Dysfunction, Chronic Stress, Neuroinflammation, and Neurodegeneration.International journal of molecular sciences · 2026Review
- PT320, a GLP-1 receptor agonist, mitigates nucleus accumbens-associated depression- and anxiety-like behaviors in MitoPark mice of Parkinson's disease.Journal of Parkinson's disease · 2026Article
- Toward the prevention of clinically manifest Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Neuronal titration of Snca via enhancer disruption mitigates disease onset in a Parkinson's disease mouse model.Brain : a journal of neurology · 2026Article
- Review
- Associations Between Sleep and Non-Motor Symptoms in RBD-Screened Suspected Prodromal Parkinson's Disease with Hyposmia or Orthostatic Hypotension.Journal of clinical medicine · 2026Article
- Large language model analysis of real-world phone calls reveals prodromal and progressive biomarker of parkinsonism: A two-year proof-of-concept study.PLOS digital health · 2026Article
- Narrative Review of Body-First Versus Brain-First Prodromal Neuropsychiatric Symptoms in Parkinson's Disease.Cureus · 2026Review
170 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efforts to develop neuroprotective therapy for Parkinson disease (PD) are focusing on the early stages of disease, which offer the best opportunity to intervene. Early PD can be divided into preclinical, prodromal and clinical stages; in this Review, we focus on the prodromal stage and markers that can be used to identify prodromal PD. We consider the necessary properties of a marker, before providing an overview of the proven and potential markers of prodromal PD, including clinical nonmotor markers, clinical motor markers, neuroimaging markers and tissue biomarkers. Markers for which the ability to predict conversion to PD is supported by the strongest evidence include olfactory loss, REM sleep behaviour disorder and constipation. Markers with the highest diagnostic strength include REM sleep behaviour disorder, dopaminergic imaging and subtle motor parkinsonism. The lead time - the period between the appearance of a marker and conversion to PD - is highly variable between markers, ranging from 5 years for impaired motor performance to >20 years for autonomic symptoms. The cost of screening for these markers also varies dramatically: some require just questionnaires, whereas others require sophisticated scanning techniques. Finally, we summarize how prodromal and risk markers can be combined to estimate the probability that an individual has prodromal PD, with a focus on the International Parkinson Disease and Movement Disorders Society (MDS) Prodromal Parkinson Criteria.
Indexed as
Identifiers
27786242What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.